Example
Evaluable patients had a valid baseline assessment. CCyR was imputed from MMR in the extension study. Molecular data are not available for patients in some regions. Median (range) follow-up was 54 (1–155) months (CP 2nd-line). *Kaplan-Meier estimate for responders only.
Criteria used: Resistant mutation; medical history or evidence of prior TKI intolerance.
Evaluable patients had a valid baseline assessment. CCyR was imputed from MMR in the extension study. Molecular data are not available for patients in some regions. Median (range) follow-up was 54 (1–155) months (CP 2nd-line).
†Patients without evaluable baselines (MCyR n=204, CCyR n=246).
*Kaplan-Meier estimate for responders only.
Criteria used: Resistant mutation; medical history or evidence of prior TKI intolerance.
Most common new TEAEs across cohorts since Year 5 were pleural effusion (n=18), arthralgia (n=14), anaemia (n=13), increased blood creatinine (n=13) and pneumonia (n=13).
Hear Dr. Alex Lyon's views on long-term TKI treatment in an ageing patient population
Compare 2013 guidelines to those published in 2020
CCyR, complete cytogenetic response; CI, confidence interval; CML, chronic myelogenous leukaemia; CP, chronic phase; MCyR, major cytogenetic response; MMR, major molecular response; TEAE, treatment-emergent adverse
event; TKI, tyrosine kinase inhibitor.
References:
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021